Kornimate/medical-research-clean huggingface dataset:
comparison of post operative endodontic pain in patients with irreversible pulpitis treated with and without dexamethasone.

Conditions: Pain

Summary: root canal procedure is a common procedure in dentistry. acute inflammatory response in peri-radicular tissues after root canal treatment is the main cause of post op pain. potential solution: the current study will assess effect of dexamethasone administered as periapical infiltration in reducing post-instrumentation pain. research goal: pain score of patients treated with dexamethasone infiltration will be less compared to patients treated with nsaids alone after canal instrumentation.

acute inflammatory response in peri-radicular tissues after root canal treatment is the main cause of post op pain. the peak inflammatory response occurs after 24 - 48 hours of root canal instrumentation. as management of post-endodontic pain is still a challenge for clinicians several drugs which include nsaids, acetaminophen, opioids and steroids are used to reduce the inflammatory response. corticosteroids possess anti-inflammatory efficacy, and they prevent the production and release of inflammatory mediators at the site of tissue injury thus reducing the signs \& symptoms of inflammation such as pain, swelling \& loss of function. dexamethasone is a potent corticosteroid that has the ability to reduce the production of proinflammatory cytokines. dexamethasone can be administered orally, or as an intraosseous, intra ligament periapical \& intracanal injection. dexamethasone is effective in alleviating pain in first 24 hours post endodontic treatment. previous research on the effect of dexamethasone injection on post-endodontic treatment pain in patients presenting with necrotic pulp treated with single visit endodontic treatment reported 25% post operative pain occurrence and 9% when treated with dexamethasone. study goal : the current study will assess effect of dexamethasone administered as periapical infiltration in reducing post-instrumentation pain as compared to the prescription of nsaids only. if dexamethasone infiltration is effective in pain relief after endodontic treatment, it can be a useful adjunct in managing patients presenting with acute pulpal pain.

Eligibility criteria:
inclusion criteria: * patients of age 18-50 years * maxillary molar and premolar teeth * pt diagnosed with irreversible pulpitis with or without apical periodontitis exclusion criteria: * teeth with calcified canals. * teeth with incompletely formed apices. * teeth requiring retreatment. * taking analgesics, anti-inflammatory, or tri-cyclic anti-depressants for their medical conditions. * teeth with grade ii or iii mobility (more than 2 mm) * pregnant patients * pt who are immunocompromised (uncontrolled diabetes mellitus, renal impairment)

Keywords: postoperative pain root canal therapy dexamethasone pulpitis
adipose tissue expandability and type 2 diabetes

Conditions: Type2 Diabetes Mellitus

Summary: the goal of the study is to analyze deviations in adipogenic potential and metabolic properties of preadipocytes in subjects with genetic predisposition to type 2 diabetes, and thus identify factors that underlie hypertrophic growth of adipose tissue associated with the development of this disease.

adipose tissue (at) expands in response to excessive energy intake by hyperplasia or hypertrophy. while hyperplasia is associated with preservation of insulin sensitivity, hypertrophic at exerts a number of metabolic defects. the mechanisms by which hyperplasia is suppressed at the expense of at hypertrophy remain unknown, but it is expected that the hypertrophy of adipocytes is primarily driven by insufficient recruitment and differentiation of available preadipocytes. the limitation of hyperplasia occurs already in non-obese healthy subjects who are genetically predisposed to type 2 diabetes. using these and control subjects, the limex project aims to analyze the mechanisms of at expandability. the project will combine in vivo characterization of at and in vitro studies on human preadipocytes derived from at biopsies obtained during clinical study. in vitro, proliferation, adipogenesis and lipogenesis of adipose cells will be monitored and these properties will be related to the degree of at hypertrophy in vivo, insulin sensitivity and genetic predisposition to metabolic complications.

Eligibility criteria:
inclusion criteria: * healthy non-obese men * subject has genetic predisposition for t2dm- i.e. two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) diagnosed with t2dm or * subject without any family history of t2dm. exclusion criteria: * any prior history of obesity * elevated triglyceride concentration (above 1.7 mmol/l) * hypertension * thyroid or other endocrine disease * smoking * drug abuse

Keywords: type 2 diabetes adipose tissue preadipocytes expandability hypertrophy hyperplasia lipogenesis adipogenesis insulin sensitivity
remote temperature monitoring of patients at risk for developing fever

Conditions: Fever; Cancer; Remote Patient Monitoring

Summary: the purpose of this program is to evaluate remote temperature monitoring in cancer patients at risk of fever and infection due to chemotherapy treatment. the main questions it aims to answer are: * does remote temperature monitoring reduce the number of days spent inpatient * what out-of-pocket cost can a patient expect to incur for participating in remote temperature monitoring * the number of billable cpt codes that will be generated by providing remote temperature monitoring researchers will compare compliant and non-compliant patients to assess if compliance with remote temperature monitoring is associated with a decrease in the number of days spent inpatient. patients will * wear the thermometer for the duration of their participation in the study * have their temperature monitored continuously * receive alerts on their phone when their temperature exceeds a threshold for a sustained duration, configurable by their physician * respond to texts or calls from remote monitors when an alert is triggered


Eligibility criteria:
inclusion criteria: * subject is at risk of a fever post discharge. * subject is ≥ 18 years or older. * subject has an ios or android phone, or is able to operate an aion provided smartphone device. * subject is willing to install the tempshield app on his/her phone. * subject is willing to allow aion to send text reminders to take temperature or complete surveys. * subject is willing to take an oral temperature as directed by their care plan. * subject is willing to configure the phone to ensure these notifications are delivered, even when phone is in a "no notification" mode. * subject or subject caretaker is able and willing to complete subject surveys. * subject is willing and able to provide written informed consent in english. * subject is willing and able to comply with all program procedures, requirements, assessments, visits, and complete questionnaires. * english speakers exclusion criteria: * unable to provide informed consent * subjects with a history of medical adhesive-related skin injury (marsi) * subjects with no available placement that avoids open wounds or traumatized skin (burns. blisters. etc.) * non-english speakers: the mobile application is only currently available in english. future development will include other languages. * subjects receiving prophylactics that could induce fever. * subjects with a silicon allergy * subject does not have ios or android phone, and is unable to operate an aion provided smartphone device. * subjects who are not willing to take an oral temperature per their care plan.

Keywords: fever infection sepsis cancer chemotherapy immunocompromised temperature wearable remote patient monitoring
a study of quintuple therapy to treat covid-19 infection

Conditions: COVID-19; Corona Virus Infection; Coronavirus-19; Sars-CoV2

Summary: this is a phase ii interventional study will test the efficacy of quintuple therapy (hydroxychloroquine, azithromycin, vitamin c, vitamin d, and zinc) in the treatment of patients with covid-19 infection).

in this study patients will be treated with a combination therapy to determine if this combination can effectively treat covid-19. treatment will last ten days. the study will last 24 weeks.

Eligibility criteria:
1. informed consent provided electronically via the edc, demonstrating that the subject understands the procedures required for the study and the purpose of the study 2. male or female subjects 18 years of age and up 3. subjects must agree to practice at least two highly effective methods of birth control for the duration of the study. this includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. at least one of these must be a barrier method. subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized) 4. diagnosis of covid-19 by rt-pcr exclusion criteria 1. refusal to provide informed consent 2. diarrhea prior to infection 3. any comorbidities which, in the opinion of the investigator, constitute health risk for the subject 4. any contraindications for treatment with hydroxychloroquine 1. hypoglycemia 2. known g6pd deficiency 3. porphyria 4. anemia 5. neutropenia 6. alcoholism 7. myasthenia gravis 8. skeletal muscle disorders 9. maculopathy 10. changes in visual field 11. liver disease 12. psoriasis 5. anemia from pyruvate kinase and g6pd deficiencies 6. abnormal ekg with qt prolongation acquired or from birth 7. allergies to 4-aminoquinolines 8. history of jaundice or high fevers prior to developing covid-19 9. treatment with any of the medications listed in appendix ii 10. treatment with any other drug not listed that affects the qt interval 11. treatment with any anti-epileptic drug, whether prescribed for seizures or otherwise. 12. pregnant or breastfeeding women
different types of electrostimulation probes during ionm

Conditions: Thyroid Diseases

Summary: intraoperative nerve monitoring is often used in many centers during thyroidectomy. according to the investigators' knowledge, there's no study showing superiority between bipolar and monopolar stimulation probes used for nerve monitoring during thyroid surgery. in this study, the investigators aimed to compare two different types of probes and find out superiorities.twenty-one patients who underwent primary total thyroidectomy or hemithyroidectomy were included in the study. during surgery, amplitude and latency values obtained in the same patient with both bipolar and monopolar stimulation probes from 10 different anatomical spots \[vagal nerve, recurrent laryngeal nerve inferior portion, recurrent laryngeal nerve superior portion, external branch of superior laryngeal nerve (ebsln)\] were recorded prospectively, both when sheath was intact and after being dissected.


Eligibility criteria:
inclusion criteria: * who underwent thyroid surgery exclusion criteria: * perioperative loss of electromyographic(emg) signal (los) during intraoperative nerve monitorization * patients with additional pathology that may affect vocal cord function, * abnormal preoperative laryngeal examination * history of thyroid, vocal cord or other neck surgery * advanced cancer, rln, esophageal or trachea invasion

Keywords: ionm thyroidectomy bipolar probe monopolar probe
a phase i, multicenter, open label study on the effects of sndx-275 on expression of biomarkers in subjects with newly diagnosed breast cancer

Conditions: Breast Cancer

Summary: the primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after sndx-275 administration.


Eligibility criteria:
inclusion criteria: * is scheduled for breast biopsy due to a suspicious mass palpable or ≥1 cm on mammogram * must be able to receive two doses of study medication 7 days apart prior to surgery * has histologically confirmed invasive breast cancer with er positive, er and/or pr negative histology or triple negative (for er, pr, her-2) histology * has an ecog performance status ≤ 2 * has no clinically significant laboratory or cardiac abnormalities * has a negative serum pregnancy test at screening as is either post menopausal, sterile or willing to use an approved method of contraception. * is able to swallow and retain oral medication exclusion criteria: * has a concomitant medical condition that precludes adequate study treatment compliance or assessment, such as: a. bleeding disorders that would increase risks of additional core biopsy for biomarkers b. morbid obesity * is currently receiving treatment with a medication on the prohibited medication list * has allergy to benzamides or inactive components of study drug * is participating in another clinical trial or has received another investigational agent within 30 days prior to informed consent

Keywords: breast cancer
efficacy and safety of sofosbuvir/velpatasvir fixed dose combination for 12 weeks in adults with chronic hepatitis c virus (hcv) and human immunodeficiency virus (hiv)-1 coinfection

Conditions: Hepatitis C Virus Infection

Summary: the primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (sof/vel) for 12 weeks in participants with chronic hcv infection who were coinfected with hiv-1.


Eligibility criteria:
key inclusion criteria: * hcv rna ≥ 10\^4 iu/ml at screening * hcv genotype 1, 2, 3, 4, 5, 6 * cirrhosis determination, a fibroscan or liver biopsy may be required * hiv-1 infection * use of protocol specified method(s) of contraception * screening laboratory values within defined thresholds key exclusion criteria: * clinically-significant illness (other than hcv or hiv) or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol * current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (hcc) or other malignancy (with the exception of certain resolved skin cancers) * screening ecg with clinically significant abnormalities * pregnant or nursing female or male with pregnant female partner * infection with hepatitis b virus (hbv) * use of any prohibited concomitant medications as described in the protocol * chronic use of systemically administered immunosuppressive agents note: other protocol defined inclusion/ exclusion criteria may apply.
a study in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma

Conditions: Ovarian Cancer

Summary: the purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.

to determine the overall response rate of cetuximab alone in subjects with ovarian or primary peritoneal carcinoma who have persistent or recurrent disease following 1-2 previous regimens of chemotherapy. potential relationship between response, dose, and the occurence of rash in the treatment of subjects who have stable disease after the initial 6 weeks of treatment, time to progression, and 1 yr survival.

Eligibility criteria:
inclusion criteria: * subjects must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma. histologic confirmation of the original primary tumor is required. * egfr expression must be positive as determined by an outside reference lab * subjects must have had a treatment-free interval following platinum of \<12 mos * all subjects must have measurable disease at baseline * subjects must have at least one recurrent lesion to be used to assess response * recovery from effect of recent surgery, radiotherapy or chemotherapy exclusion criteria: * subjects with other invasive malignancies (including peritoneal mesotheliomas) * subjects with unstable cardiac disease or mi within 6 mos * subjects with acute hepatitis * subjects with active or uncontrolled infection * a history of prior cetuximab or other therapy which targets the egfr pathway or prior history of prior chimerized or murine monoclonal antibody therapy

Keywords: ovarian primary peritoneal cancer persistent or recurrent ovarian cancer primary peritoneal carcinoma
comparison of three protocols for tight glycemic control in cardiac surgery patients

Conditions: Hyperglycemia

Summary: a randomized trial to compare three insulin-titration protocols for tight glycemic control in surgical icu: an absolute glucose (matias) protocol, a relative glucose change (bath) protocol, and an enhanced model predictive control algorithm (empc)

120 consecutive post-cardiac surgery patients randomized to the three protocols with a target glycemia range from 4.4 to 6.1 mmol/l. intravenous insulin was administered continuously or in combination with insulin boluses (matias protocol). blood glucose was measured in 1-4 hour intervals as requested by protocols.

Eligibility criteria:
inclusion criteria: * patients admitted to the postoperative icu after elective cardiac surgery exclusion criteria: * insulin allergy

Keywords: tight glycemia control cardiac surgery patients
evaluating a mindful eating curriculum, "savor the flavor"

Conditions: Eating Behavior

Summary: the overall goal of this study is to conduct a preliminary evaluation of the feasibility and efficacy of the "savor the flavor" intervention.

the overall goal of this study is to conduct a preliminary evaluation of the feasibility and efficacy of the "savor the flavor" intervention. the goal of this curriculum is to teach children how to savor foods and slow down while eating by focusing on the sensory experience of eating. the intervention will also teach children attention control techniques so that they are better able to delay consumption of high energy, low nutrition foods, when appropriate.the study will also evaluate a modified version of the eating in the absence of hunger task for use in a preschool classroom setting.

Eligibility criteria:
child inclusion criteria: * child must be enrolled in a head start preschool center * child must be between the ages of 2 and 6 years old child exclusion criteria: * food allergy or restriction to foods included in protocol parent inclusion criteria: * parent or other primary caregiver of a child enrolled in the study * 18 years of age or older * english speaking parent exclusion criteria: - none teacher inclusion criteria: * actively employed as an early childhood education provider in the head start classroom where intervention is delivered * 18 years of age or older teacher exclusion criteria: - none

Keywords: mindfullness eating snacking obesity children
immediate effects of self-myofascial release on latent trigger point sensitivity

Conditions: Trigger Points

Summary: latent myofascial trigger points (lmtrp) which impair neuromuscular performance occur in both, patients and asymptomatic subjects. as evidence suggests that lmtrp can transform into active trigger points, therapy seems warranted. besides other modalities, self-massage using foam rollers (self-myofascial release) has been applied as a treatment. however, there is no data on the efficacy of this method concerning lmtrp. thus, the present study aims to evaluate the effects of different forms of self-myofascial release on lmtrp pain. healthy patients with lmtrp in the calf are randomly allocated to one of three groups: 1) 90s static compression of the most sensitive lmtrp by means of the foam roll, 2) dynamic self-myofascial release rolling back and forth on the calf muscles for 90s using a foam roller, 3) placebo laser acupuncture of the most sensitive lmtrp. all subjects participate in a familiarization session with the foam roller one week prior to treatments. as an outcome, pressure pain threshold is assessed with an algometer. the investigators hypothesize, that static compression can reduce pressure pain of lmtrp more effective than dynamic self-myofascial release. the investigators further expect that placebo treatment will be the least effective method.


Eligibility criteria:
inclusion criteria: * at least one diagnosed latent myofascial trigger point in the calf * age 18 to 65 years * written informed consent exclusion criteria: * active myofascial trigger point in the calf * regular intake of drugs or within past 48 hours * severe psychiatric, neurological, orthopaedic, cardiovascular or endocrine diseases * pregnancy or nursing period * any condition that negatively influences current quality of life
insulin glargine at bedtime or in am versus nph

Conditions: Type 2 Diabetes Mellitus

Summary: to compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly nph insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.

insulin glargine has a longer action than compared to nph insulin, but whether this results in improved control when used as a once-nightly or morning basal insulin injection in type 2 diabetic patients who are inadequately controlled on combination oral agents has been controversial. inner city ethnic minority patients with diabetes are a particularly challenging population of diabetic patients to treat. this study investigates whether insulin glargine may be a more effective or safer first-line basal insulin than nph in this population.

Eligibility criteria:
inclusion criteria: * male or female, age 18-75 * type 2 diabetes diagnosed for at least 1 year * treatment with stable doses of oral agents (alone or in combination) for at least 2 months * inadequate glycemic control (hemoglobin a1c ≥ 7.5%) on maximum-tolerated doses of a sulfonylurea, metformin and a thiazolidinedione * no past history of chronic insulin use (other than treatment of gestational diabetes or hospitalizations of less than 1 week in duration) * hemoglobin a1c between 7.5% and 12% * body mass index (bmi) between 20 and 40 kg/m2 exclusion criteria: * current or previous chronic use of insulin (other than for treatment of gestational diabetes) * history of confirmed (or clinical suspicion of) type 1 diabetes * female subjects of childbearing potential who are sexually active and not using a reliable form of contraception * current pregnancy or lactation. * subjects for whom insulin therapy is contraindicated or for whom, in the opinion of the investigator, therapy with insulin is not indicated * subjects with advanced proliferative diabetic retinopathy * subjects who work night shifts or who are unable to stay on a consistent daily meal schedule * history of any clinically significant renal, hepatic, cardiovascular, neurological, endocrinological or other major systemic disease that, in the opinion of the investigator, may make implementation of the protocol or interpretation of the data difficult. * subjects who will likely require or initiate therapy with drugs which may interfere with glucose metabolism during the course of the study * subjects who are in another investigational study or have received another investigational medication within 30 days of study entry * subjects who are unable or unwilling to comply with all components of the study protocol, including contacting the investigators at specified times and attending all scheduled follow-up visits.

Keywords: glargine type 2 diabetes basal insulin